MSD Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
✨Continue to leverage science-driven business development to augment and complement our robust pipeline, said Dr.Dean Y.Li, president, MSD Research Laboratories.“Through this agreement, we aim to build on our experience targeting incretin biology to evaluate HS-10535 and its potential to provide additional cardiometabolic benefits beyond weight reduction.” ✨Under the agreement, Hansoh Pharma has granted MSD an … Read more